Nama's AI scorecard currently rates Alkermes Hold (5.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is ALKS's P/E ratio?

Alkermes trades at a trailing price-to-earnings ratio of 21.6.

When does ALKS report earnings?

Alkermes's next scheduled report is on Feb 24, 2027. Analysts expect EPS of $0.09.

What is the ALKS price target?

The median analyst price target from 19 analysts is $58.00, with a range of $38.00 – $83.00.

Is ALKS Shariah compliant?

Nama's AAOIFI-style screen reads Alkermes as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

Alkermes (ALKS)

Healthcare · Drug Manufacturers Specialty Generic · NASDAQ

Alkermes (ALKS) is a Healthcare company in the Drug Manufacturers Specialty Generic industry. It has a market capitalization of $7.71B, a trailing price-to-earnings ratio of 21.6 and a free-cash-flow yield of 6.2%. Over the most recent reported fiscal year, revenue declined 5.2% and free cash flow per share grew 18.7%. Nama's AI scorecard rates it Hold, 5.5 out of 10. On 12-month momentum it ranks in the rising band of its market.

AI scorecard

Hold · 5.5/10

The sections balance. As of Nov 7, 2026.

Momentum

Rising · +30.8% over 12 months ex. last

Second-best fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-17.6%

How far the last close sits under the highest price of the past five years.

Market cap	$7.71B
Trailing P/E	21.6
Price / book	4.4
Price / sales	4.6
FCF yield	6.2%
Dividend yield	—
Gross margin	86.6%
Operating margin	12.3%
Net margin	9.8%
Revenue growth (YoY)	-5.2%
Revenue growth (3-yr annual)	+9.9%
EPS growth (YoY)	-27.8%
FCF/share growth (YoY)	+18.7%
Beta	0.3
Exchange	NASDAQ
Sector	Healthcare
Industry	Drug Manufacturers Specialty Generic

ALKS earnings

Next report: Feb 24, 2027 (Q4 2026, EPS estimate $0.09). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 3, 2026	$0.57	$0.25	+128.0%	$480.13M
Q2 2026	Jul 28, 2026	$0.70	$0.29	+141.4%	—
Q1 2026	May 5, 2026	$0.38	-$0.04	+1050.0%	$392.91M
Q4 2025	Feb 25, 2026	$0.48	$0.45	+6.7%	$384.55M

ALKS analyst price target

Median target $58.00 from 19 analysts, ranging $38.00 – $83.00.

Drug Manufacturers Specialty Generic peers

Ticker	Company	Market cap	P/E
TAK	Takeda Pharmaceutical	$67.16B	42.0
TEVA	Teva Pharmaceutical Industries	$49.72B	18.0
HLN	Haleon	$40.17B	21.3
ZTS	Zoetis	$32.81B	12.0
UTHR	United Therapeutics	$23.94B	21.2
VTRS	Viatris	$22.87B	7.8
NBIX	Neurocrine Biosciences	$16.66B	16.5
ELAN	Elanco Animal Health	$12.86B	24.3

Explore live ALKS data on Nama Insights →

Recent Congressional trades

Alkermes trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Oct 12, 2026
Gilbert Cisneros	House	Buy	$15,001 - $50,000	Sep 4, 2026

ALKS FAQ

Is ALKS a buy?: Nama's AI scorecard currently rates Alkermes Hold (5.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is ALKS's P/E ratio?: Alkermes trades at a trailing price-to-earnings ratio of 21.6.
When does ALKS report earnings?: Alkermes's next scheduled report is on Feb 24, 2027. Analysts expect EPS of $0.09.
What is the ALKS price target?: The median analyst price target from 19 analysts is $58.00, with a range of $38.00 – $83.00.
Is ALKS Shariah compliant?: Nama's AAOIFI-style screen reads Alkermes as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.